25 Jun 2014

Puregon (Follitropine Bêta) - France

ATC: G03GA
GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
GONADOTROPINS AND OTHER OVULATION STIMULANTS
GONADOTROPINS
Puregon

Generic Matches for Follitropine Bêta (1)
Fertavid

Last Updated on 25 Jun 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Puregon Indication

Chez les femmes adultes :
Puregon est indiqué pour le traitement de l’infertilité féminine dans les situations cliniques suivantes :
- Anovulation (y compris le syndrome des ovaires polykystiques - SOPK) chez les femmes ne répondant pas au traitement par le citrate de clomifène.
- Hyperstimulation ovarienne contrôlée pour induire le développement de follicules multiples dans le cadre des programmes de procréation médicalement assistée [par exemple, fécondation in vitro avec transfert d'embryon (FIVETE), transfert de gamètes dans les trompes (GIFT), injection intracytoplasmique de spermatozoïde (ICSI)].

Chez les hommes adultes :
- Déficience de la spermatogenèse due à un hypogonadisme hypogonadotrope.

Puregon Generic Name

Follitropine Bêta

Type

POM

Summary Product Characteristics (SPCs) Links
Résumé des Caractéristiques du Produit - Puregon (external site)

Related Learning Zones

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Selected content related to Puregon (Follitropine Bêta)

Guidelines

Puregon Marketing Information

Puregon Generic Name
Follitropine Bêta
Marketing Company
Merck Sharp & Dohme Limited
Drug Type
POM
Date of Issue, Marketing Authority

03/05/1996

Médicaments utilisés en Endocrinologie et Diabète

Back to top